NOVA1 Promotes NSCLC Proliferation and Invasion by Activating Wnt/β-catenin Signaling

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Oct 26

PMID 36284263

Authors

Lianyue Qu

Yulong Tian

Fan Wang

Zixuan Li

Affiliations

Soon will be listed here.

Abstract

Background: Neuro-oncological ventral antigen 1 (NOVA1) is a neuron-specific RNA-binding protein which regulates alternative splicing in the developing nervous system. Recent research has found that NOVA1 plays a significant role in carcinogenesis. In this paper, we examine the role of NOVA1 in non-small cell lung cancer (NSCLC) and its underlying molecular mechanisms.

Methods: The expression of NOVA1 in NSCLC was detected by immunohistochemistry and correlations between NOVA1 expression and clinicopathological factors were analyzed by chi-square tests. Kaplan-Meier survival analysis and the Cox regression model were used to evaluate the predictive effect of prognostic factors. Western blotting, Cell Counting Kit-8, colony formation, apoptosis, migration and invasion assays were used to detect the effects of silencing (si)NOVA1 RNA on Wnt/β-catenin signaling and biological behavior in NSCLC cell lines.

Results: Our study showed that expression of NOVA1 was up-regulated and significantly correlated with poor differentiation (p = 0.020), advanced TNM stage (P = 0.001), T stage (P = 0.001) and lymph node metastasis (P = 0.000) as well as the expression of β-catenin (P = 0.012) in NSCLC. The down-regulation of NSCLC by siRNA significantly inhibited proliferation, migration and invasion and promoted apoptosis in NSCLC cells. Expression of Wnt signaling molecules, including β-catenin, activated β-catenin, cyclin D1, matrix metalloproteinase (MMP)-2 and MMP-7, was also significantly reduced by siNOVA1. The inhibition of Wnt/β-catenin signaling in A549 and H1299 cells by siNOVA1 was reversed after treatment with a β-catenin expression plasmid.

Conclusion: The present study suggests that NOVA1 may serve as a potential prognosis biomarker in NSCLC. High NOVA1 expression was associated with poor survival rate. Finally, in vitro experiments verified that NOVA1 promotes NSCLC cell proliferation and invasion by regulating Wnt/β-catenin signaling.

Citing Articles

NTRK fusion promotes tumor migration and invasion through epithelial-mesenchymal transition and closely interacts with ECM1 and NOVA1.

Zeng S, Jiang K, Ge J, Tang M, Wen Y, Ma X BMC Cancer. 2024; 24(1):1502.

PMID: 39639242 PMC: 11619257. DOI: 10.1186/s12885-024-13271-w.

RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer.

Uchida Y, Kurimoto R, Chiba T, Matsushima T, Oda G, Onishi I EMBO Rep. 2024; 25(12):5352-5382.

PMID: 39420119 PMC: 11624195. DOI: 10.1038/s44319-024-00282-8.

Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.

Zhang Z, Westover D, Tang Z, Liu Y, Sun J, Sun Y J Transl Med. 2024; 22(1):565.

PMID: 38872189 PMC: 11170811. DOI: 10.1186/s12967-024-05380-8.

IGF2BP1 facilitates non-small cell lung cancer progression by regulating the KIF2A-mediated Wnt/β-catenin pathway.

Sun M, Wang L, Ge L, Xu D, Zhang R Funct Integr Genomics. 2023; 24(1):4.

PMID: 38102458 DOI: 10.1007/s10142-023-01275-x.

Regulation of Epithelial-Mesenchymal Transitions by Alternative Splicing: Potential New Area for Cancer Therapeutics.

Li L, Zheng J, Oltean S Genes (Basel). 2023; 14(11).

PMID: 38002944 PMC: 10671305. DOI: 10.3390/genes14112001.

References

Li H, Lv B, Kong L, Xia J, Zhu M, Hu L . Nova1 mediates resistance of rat pheochromocytoma cells to hypoxia-induced apoptosis via the Bax/Bcl-2/caspase-3 pathway. Int J Mol Med. 2017; 40(4):1125-1133. PMC: 5593465. DOI: 10.3892/ijmm.2017.3089. View

Graus F, Rowe G, Fueyo J, Darnell R, Dalmau J . The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett. 1993; 150(2):212-4. DOI: 10.1016/0304-3940(93)90538-v. View

Dredge B, Darnell R . Nova regulates GABA(A) receptor gamma2 alternative splicing via a distal downstream UCAU-rich intronic splicing enhancer. Mol Cell Biol. 2003; 23(13):4687-700. PMC: 164843. DOI: 10.1128/MCB.23.13.4687-4700.2003. View

Cao Y, Zhang F, Wang H, Bi C, Cui J, Liu F . LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis. Mol Cell Biochem. 2020; 476(1):279-292. DOI: 10.1007/s11010-020-03904-6. View

Zhang Y, Zhu J, Yin J, Tang W, Guo Y, Shen X . High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma. PLoS One. 2014; 9(3):e90955. PMC: 3946567. DOI: 10.1371/journal.pone.0090955. View

Jin L, Li H, Wang J, Lin D, Yin K, Lin L . MicroRNA-193a-5p exerts a tumor suppressor role in glioblastoma via modulating NOVA1. J Cell Biochem. 2018; 120(4):6188-6197. DOI: 10.1002/jcb.27906. View

Gimenez M, Marie S, Oba-Shinjo S, Uno M, Izumi C, Oliveira J . Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma. BMC Cancer. 2015; 15:481. PMC: 4502388. DOI: 10.1186/s12885-015-1473-9. View

Tang S, Zhao Y, He X, Zhu J, Chen S, Wen J . Identification of NOVA family proteins as novel β-catenin RNA-binding proteins that promote epithelial-mesenchymal transition. RNA Biol. 2020; 17(6):881-891. PMC: 7549617. DOI: 10.1080/15476286.2020.1734372. View

Qu L, Tian Y, Hong D, Wang F, Li Z . Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p. Int J Med Sci. 2022; 19(2):338-351. PMC: 8795807. DOI: 10.7150/ijms.66040. View

10.

Kim E, Yoon S, Kim S, Yang W, Cho Y, Kim S . Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas. J Pathol Transl Med. 2016; 50(2):104-12. PMC: 4804152. DOI: 10.4132/jptm.2016.02.08. View

11.

Luo Y, Hao T, Zhang J, Zhang M, Sun P, Wu L . MicroRNA-592 suppresses the malignant phenotypes of thyroid cancer by regulating lncRNA NEAT1 and downregulating NOVA1. Int J Mol Med. 2019; 44(3):1172-1182. DOI: 10.3892/ijmm.2019.4278. View

12.

Ule J, Ule A, Spencer J, Williams A, Hu J, Cline M . Nova regulates brain-specific splicing to shape the synapse. Nat Genet. 2005; 37(8):844-52. DOI: 10.1038/ng1610. View

13.

Kolegova E, Shashova E, Kostromitskii D, Dobrodeev A, Kondakova I . Beta-Catenin in Non-Small Cells Lung Cancer and Its Association with Proteasomes. Bull Exp Biol Med. 2020; 168(5):677-680. DOI: 10.1007/s10517-020-04779-9. View

14.

Ludlow A, Wong M, Robin J, Batten K, Yuan L, Lai T . NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun. 2018; 9(1):3112. PMC: 6079032. DOI: 10.1038/s41467-018-05582-x. View

15.

Jensen K, Dredge B, Stefani G, Zhong R, Buckanovich R, Okano H . Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron. 2000; 25(2):359-71. DOI: 10.1016/s0896-6273(00)80900-9. View

16.

Hong Y, Xu G, Yu G, Zhou J, Liu Q, Ni J . The RNA binding protein neuro-oncological ventral antigen 1 (NOVA1) regulates IL-6 mRNA stability to enhance JAK2-STAT3 signaling in CRC. Surg Oncol. 2019; 31:67-74. DOI: 10.1016/j.suronc.2019.09.009. View

17.

Sun S, Wang R, Yi S, Li S, Wang L, Wang J . Roles of the microRNA‑338‑3p/NOVA1 axis in retinoblastoma. Mol Med Rep. 2021; 23(5). PMC: 8008220. DOI: 10.3892/mmr.2021.12033. View

18.

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K . Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11:943-953. PMC: 6345192. DOI: 10.2147/CMAR.S187317. View

19.

Stewart D . Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2013; 106(1):djt356. DOI: 10.1093/jnci/djt356. View

20.

Ule J, Jensen K, Ruggiu M, Mele A, Ule A, Darnell R . CLIP identifies Nova-regulated RNA networks in the brain. Science. 2003; 302(5648):1212-5. DOI: 10.1126/science.1090095. View